The estimated Net Worth of Johan M. Spoor is at least $1.17 Milión dollars as of 28 December 2018. Johan Spoor owns over 38,583 units of AzurRx BioPharma Inc stock worth over $1,168,229 and over the last 8 years Johan sold AZRX stock worth over $0.
Sign up
Johan Spoor AZRX stock SEC Form 4 insiders trading
Johan has made over 1 trades of the AzurRx BioPharma Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Johan bought 38,583 units of AZRX stock worth $50,158 on 28 December 2018.
The largest trade Johan's ever made was buying 38,583 units of AzurRx BioPharma Inc stock on 28 December 2018 worth over $50,158. On average, Johan trades about 7,717 units every 0 days since 2017. As of 28 December 2018 Johan still owns at least 338,617 units of AzurRx BioPharma Inc stock.
You can see the complete history of Johan Spoor stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Johan Spoor's mailing address?
Johan's mailing address filed with the SEC is C/O AZURRX BIOPHARMA, INC., 760 PARKSIDE AVE SUITE 304, BROOKLYN, NY, 11226.
Insiders trading at AzurRx BioPharma Inc
Over the last 8 years, insiders at AzurRx BioPharma Inc have traded over $510,400 worth of AzurRx BioPharma Inc stock and bought 335,700 units worth $727,436 . The most active insiders traders include Charles J Casamento, Edmund Burke Jr. Ross a Partners Llcbalk Matthew Pe.... On average, AzurRx BioPharma Inc executives and independent directors trade stock every 82 days with the average trade being worth of $262,052. The most recent stock trade was executed by Johan M. Spoor on 28 December 2018, trading 38,583 units of AZRX stock currently worth $50,158.
What does AzurRx BioPharma Inc's logo look like?
Complete history of Johan Spoor stock trades at AzurRx BioPharma Inc
AzurRx BioPharma Inc executives and stock owners
AzurRx BioPharma Inc executives and other stock owners filed with the SEC include:
-
James R. Sapirstein R.Ph., M.B.A.,
CEO, Pres & Non-Independent Director -
James Pennington,
Chief Medical Officer -
James Sapirstein,
President, Chief Executive Officer, Director -
Alastair Riddell,
Independent Director -
Edward Borkowski,
Independent Chairman of the Board -
Vern Schramm,
Independent Director -
Charles Casamento,
Independent Director -
Gregory Oakes,
Independent Director -
Daniel Schneiderman,
Chief Financial Officer -
Martin Krusin M.B.A.,
Sr. VP of Corp. Devel. -
Johan M. Spoor,
-
Partners Llcbalk Matthew Pe...,
-
Edmund Burke Jr. Ross,
-
Maged Shenouda,
CHIEF FINANCIAL OFFICER -
Daniel Dupret,
CHIEF SCIENTIFIC OFFICER -
Mary Theresa Coelho,